Paclitaxel is under clinical development by Samyang Biopharmaceuticals and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Paclitaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Paclitaxel overview

Paclitaxel (Genexol-PM) belongs to the class compounds called taxanes, which acts as anti-cancer agents. It is formulated as lyophilized powder for solution. It is administered as intravenous infusion. Genexol-PM is indicated for breast cancer and non-small cell lung cancer. It is also indicated for the treatment of metastatic ovarian and breast cancer.

The drug candidate is under development for the treatment of esophageal cancer, advanced biliary tract cancer, advanced or metastatic urothelial cell carcinoma, metastatic adenocarcinoma of the pancreas, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, cervical cancer and uterine corpus cancer. It was also under development for the treatment of metastatic breast cancer, non-small cell lung cancer, bladder cancer, ovarian cancer, gastric cancer and pancreatic cancer.

Samyang Biopharmaceuticals overview

Samyang Biopharmaceuticals (Samyang Biopharm), a subsidiary of Samyang Holdings Corp, develops pharmaceutical products and medical devices. The company’s pharmaceutical products include anti-cancer drugs, injections, transdermal patches, active pharmaceutical ingredients (APIs), and oncology formulations. It also focuses on the development and commercialization of medical devices such as biodegradable surgical sutures, synthetic absorbable suture materials, partially absorbable lightweight mesh, biodegradable dental implant materials, biosurgery products, and other raw materials. Samyang Biopharm offers its products for the treatment of breast, lung, ovarian, head, and neck cancers. Samyang Biopharm’s key brands include Genexol, Nicostop, Nanoxel, Trisorb, and Monosorb, among others. The company, through its subsidiaries, collaborates with biotechnology, pharmaceutical, venture firms, research institutes, and universities to develop new products and drug delivery technologies. Samyang Biopharm is headquartered in Seongnam, Gyeonggi-do, South Korea.

For a complete picture of Paclitaxel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.